Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC) Meeting Abstract
| Authors: | Beltran, H.; Johnson, M. L.; Jain, P.; Schenk, E. L.; Sanborn, R. E.; Thompson, J. R.; Dowlati, A.; Mamdani, H.; Aggarwal, R. R.; Anand, B. S.; Gramza, A. W.; Choudhury, N. J. |
| Abstract Title: | Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401879 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.8090 |
| Notes: | Meeting Abstract: 8090 -- Source: Wos |
